Baxter International Inc. (NYSE: BAX) saw its shares plummet 6.60% in pre-market trading on Thursday following the release of its second-quarter 2025 financial results, which fell short of analysts' expectations. The healthcare company's earnings report revealed disappointing figures across multiple key metrics, triggering a significant sell-off among investors.
For the second quarter, Baxter reported adjusted earnings per share (EPS) of $0.54, missing the IBES estimate of $0.61. The company's revenue came in at $2.81 billion, slightly below the expected $2.823 billion. Notably, Baxter's adjusted operating income for the quarter was $423 million, substantially lower than the IBES estimate of $452.3 million. These misses on both top and bottom lines have raised concerns about the company's performance and near-term growth prospects.
While Baxter provided a positive outlook for the third quarter and full year, with projected sales growth from continuing operations of 6% to 7% on a reported basis, it seems the guidance failed to alleviate investor worries. The company forecasts Q3 adjusted earnings from continuing operations, before special items, of $0.58 to $0.62 per diluted share, and full-year adjusted EPS of $2.42 to $2.52. However, these projections appear to have fallen short of market expectations, contributing to the sharp decline in Baxter's stock price during pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.